IAP-based selective RIPK2 degrader
prolonged PD w/ 0.15 mpk SC Q3D dosing
E3 binder switch and property-based opt.
Commun. Biol., Mar. 20, 2020
GlaxoSmithKline, Stevenage, UK / PMCC
“PROTAC 6”
1 min read
“PROTAC 6” (GlaxoSmithKline (GSK) IAP-based selective RIPK2 degrader with prolonged in vivo PD)
Search By Structure
- CC-92480
- “PROTAC 6”
- GSK620
- Merck hArg1 inhibitor
- Merck IDO1 inhibitor
- Constellation EZH2 inhibitor
- Arcus CD73 inhibitor
- MK-6884
- Sulfopin
- M3814
- Remibrutinib
Molecules of the Month
2023
2022
2021
2020